-
1
-
-
77957366667
-
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer
-
Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, Notari KH, Peach M, Hei YJ, Patterson SD (2010) Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 95: 5018-5027.
-
(2010)
J Clin Endocrinol Metab
, vol.95
, pp. 5018-5027
-
-
Bass, M.B.1
Sherman, S.I.2
Schlumberger, M.J.3
Davis, M.T.4
Kivman, L.5
Khoo, H.M.6
Notari, K.H.7
Peach, M.8
Hei, Y.J.9
Patterson, S.D.10
-
2
-
-
0002429117
-
A confidence interval for the median survival time
-
Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38: 29-41.
-
(1982)
Biometrics
, vol.38
, pp. 29-41
-
-
Brookmeyer, R.1
Crowley, J.2
-
3
-
-
79956328903
-
Molecular mechanisms and clinical applications of angiogenesis
-
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
-
(2011)
Nature
, vol.473
, pp. 298-307
-
-
Carmeliet, P.1
Jain, R.K.2
-
4
-
-
33845188987
-
Expression and prognostic significance of angiopoietin in colorectal carcinoma
-
Chung YC, Hou YC, Chang CN, Hseu TH (2006) Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol 94: 631-638.
-
(2006)
J Surg Oncol
, vol.94
, pp. 631-638
-
-
Chung, Y.C.1
Hou, Y.C.2
Chang, C.N.3
Hseu, T.H.4
-
5
-
-
77958042477
-
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: Implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody
-
Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SJ, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcon BL, McDonald DM, Li L, Boone T, Kendall R, Radinsky R, Oliner JD (2010) Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9: 2641-2651.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2641-2651
-
-
Coxon, A.1
Bready, J.2
Min, H.3
Kaufman, S.4
Leal, J.5
Yu, D.6
Lee, T.A.7
Sun, J.R.8
Estrada, J.9
Bolon, B.10
McCabe, J.11
Wang, L.12
Rex, K.13
Caenepeel, S.14
Hughes, P.15
Cordover, D.16
Kim, H.17
Han, S.J.18
Michaels, M.L.19
Hsu, E.20
Shimamoto, G.21
Cattley, R.22
Hurh, E.23
Nguyen, L.24
Wang, S.X.25
Ndifor, A.26
Hayward, I.J.27
Falcon, B.L.28
McDonald, D.M.29
Li, L.30
Boone, T.31
Kendall, R.32
Radinsky, R.33
Oliner, J.D.34
more..
-
6
-
-
77956103532
-
A review of the most promising biomarkers in colorectal cancer: One step closer to targeted therapy
-
Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB (2010) A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 15: 699-731.
-
(2010)
Oncologist
, vol.15
, pp. 699-731
-
-
Deschoolmeester, V.1
Baay, M.2
Specenier, P.3
Lardon, F.4
Vermorken, J.B.5
-
7
-
-
84874566567
-
Phase 2 randomized, doubleblind, placebo-controlled study of AMG 386 in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
-
doi: 10.1093/annonc/mds502 in press
-
Eatock M, Tebbutt N, Bampton CL, Strickland A, Valladares-Ayerbes M, Swieboda-Sadlej A, Van Cutsem E, Nanayakkara N, Sun Y-N, Zhong D, Bass MB, Adewoye AH, Bodoky G (2012) Phase 2 randomized, doubleblind, placebo-controlled study of AMG 386 in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol; doi: 10.1093/annonc/mds502 (in press).
-
(2012)
Ann Oncol
-
-
Eatock, M.1
Tebbutt, N.2
Bampton, C.L.3
Strickland, A.4
Valladares-Ayerbes, M.5
Swieboda-Sadlej, A.6
Van Cutsem, E.7
Nanayakkara, N.8
Sun, Y.-N.9
Zhong, D.10
Bass, M.B.11
Adewoye, A.H.12
Bodoky, G.13
-
8
-
-
0035910614
-
Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation
-
Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, Iba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T (2001) Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 88: 22-29.
-
(2001)
Circ Res
, vol.88
, pp. 22-29
-
-
Fujiyama, S.1
Matsubara, H.2
Nozawa, Y.3
Maruyama, K.4
Mori, Y.5
Tsutsumi, Y.6
Masaki, H.7
Uchiyama, Y.8
Koyama, Y.9
Nose, A.10
Iba, O.11
Tateishi, E.12
Ogata, N.13
Jyo, N.14
Higashiyama, S.15
Iwasaka, T.16
-
9
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson 3rd AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
O'Dwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
Schwartz, M.A.7
Benson Iii., A.B.8
-
10
-
-
78049268477
-
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
-
Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT (2010) Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103: 1407-1414.
-
(2010)
Br J Cancer
, vol.103
, pp. 1407-1414
-
-
Goede, V.1
Coutelle, O.2
Neuneier, J.3
Reinacher-Schick, A.4
Schnell, R.5
Koslowsky, T.C.6
Weihrauch, M.R.7
Cremer, B.8
Kashkar, H.9
Odenthal, M.10
Augustin, H.G.11
Schmiegel, W.12
Hallek, M.13
Hacker, U.T.14
-
11
-
-
0028022585
-
Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
-
Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54: 3723-3725.
-
(1994)
Cancer Res
, vol.54
, pp. 3723-3725
-
-
Gupta, E.1
Lestingi, T.M.2
Mick, R.3
Ramirez, J.4
Vokes, E.E.5
Ratain, M.J.6
-
12
-
-
70249114453
-
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors
-
Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS (2009) Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27: 3557-3565.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3557-3565
-
-
Herbst, R.S.1
Hong, D.2
Chap, L.3
Kurzrock, R.4
Jackson, E.5
Silverman, J.M.6
Rasmussen, E.7
Sun, Y.N.8
Zhong, D.9
Hwang, Y.C.10
Evelhoch, J.L.11
Oliner, J.D.12
Le, N.13
Rosen, L.S.14
-
14
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
15
-
-
84863012011
-
Randomized, double-blind, placebocontrolled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
-
Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt Jr. CH, Brown III JV, Covens A, Nagarkar RV, DavyM, Leath III CA, Nguyen H, Stepan DE,Weinreich DM, Tassoudji M, Sun YN, Vergote IB (2012) Randomized, double-blind, placebocontrolled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30: 362-371.
-
(2012)
J Clin Oncol
, vol.30
, pp. 362-371
-
-
Karlan, B.Y.1
Oza, A.M.2
Richardson, G.E.3
Provencher, D.M.4
Hansen, V.L.5
Buck, M.6
Chambers, S.K.7
Ghatage, P.8
Pippitt Jr., C.H.9
Brown Iii., J.V.10
Covens, A.11
Nagarkar, R.V.12
Davy, M.13
Leath Iii., C.A.14
Nguyen, H.15
Stepan, D.E.16
Weinreich, D.M.17
Tassoudji, M.18
Sun, Y.N.19
Vergote, I.B.20
more..
-
16
-
-
0041804297
-
5-fluorouracil and dihydropyrimidine dehydrogenase
-
Kubota T (2003) 5-fluorouracil and dihydropyrimidine dehydrogenase. Int J Clin Oncol 8: 127-131.
-
(2003)
Int J Clin Oncol
, vol.8
, pp. 127-131
-
-
Kubota, T.1
-
17
-
-
84862275233
-
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
-
Lu J-F, Rasmussen E, Karlan BY, Vergote IB, Navale L, Kuchimanchi M, Melara R, Stepan DE, Weinreich DM, Sun Y-N (2011) Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol 69(5): 1135-1144.
-
(2011)
Cancer Chemother Pharmacol
, vol.69
, Issue.5
, pp. 1135-1144
-
-
Lu, J.-F.1
Rasmussen, E.2
Karlan, B.Y.3
Vergote, I.B.4
Navale, L.5
Kuchimanchi, M.6
Melara, R.7
Stepan, D.E.8
Weinreich, D.M.9
Sun, Y.-N.10
-
18
-
-
0026636184
-
Influence of sex and age on fluorouracil clearance
-
Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10: 1171-1175.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1171-1175
-
-
Milano, G.1
Etienne, M.C.2
Cassuto-Viguier, E.3
Thyss, A.4
Santini, J.5
Frenay, M.6
Renee, N.7
Schneider, M.8
Demard, F.9
-
19
-
-
0033958277
-
Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
-
Milano G, McLeod HL (2000) Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 36: 37-42.
-
(2000)
Eur J Cancer
, vol.36
, pp. 37-42
-
-
Milano, G.1
McLeod, H.L.2
-
20
-
-
77953097101
-
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors
-
Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P (2010) Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 16: 3044-3056.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3044-3056
-
-
Mita, A.C.1
Takimoto, C.H.2
Mita, M.3
Tolcher, A.4
Sankhala, K.5
Sarantopoulos, J.6
Valdivieso, M.7
Wood, L.8
Rasmussen, E.9
Sun, Y.N.10
Zhong, Z.D.11
Bass, M.B.12
Le, N.13
Lorusso, P.14
-
21
-
-
0032580377
-
Interval estimation for the difference between independent proportions: Comparison of eleven methods
-
Newcombe RG (1998) Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17: 873-890.
-
(1998)
Stat Med
, vol.17
, pp. 873-890
-
-
Newcombe, R.G.1
-
22
-
-
84875229964
-
Serum soluble VCAM-1 as a valuable prognostic marker in colorectal carcinoma (abstract)
-
San Francisco CA
-
Okugawa Y, Miki C, Toiyama Y, Koike Y, Yokoe T, Saigusa S, Tanaka K, Inoue Y, Ohigashi S, Kusunoki M (2008) Serum soluble VCAM-1 as a valuable prognostic marker in colorectal carcinoma (abstract). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA.
-
(2008)
American Society of Clinical Oncology Gastrointestinal Cancers Symposium
-
-
Okugawa, Y.1
Miki, C.2
Toiyama, Y.3
Koike, Y.4
Yokoe, T.5
Saigusa, S.6
Tanaka, K.7
Inoue, Y.8
Ohigashi, S.9
Kusunoki, M.10
-
23
-
-
7944220649
-
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
-
Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516.
-
(2004)
Cancer Cell
, vol.6
, pp. 507-516
-
-
Oliner, J.1
Min, H.2
Leal, J.3
Yu, D.4
Rao, S.5
You, E.6
Tang, X.7
Kim, H.8
Meyer, S.9
Han, S.J.10
Hawkins, N.11
Rosenfeld, R.12
Davy, E.13
Graham, K.14
Jacobsen, F.15
Stevenson, S.16
Ho, J.17
Chen, Q.18
Hartmann, T.19
Michaels, M.20
Kelley, M.21
Li, L.22
Sitney, K.23
Martin, F.24
Sun, J.R.25
Zhang, N.26
Lu, J.27
Estrada, J.28
Kumar, R.29
Coxon, A.30
Kaufman, S.31
Pretorius, J.32
Scully, S.33
Cattley, R.34
Payton, M.35
Coats, S.36
Nguyen, L.37
Desilva, B.38
Ndifor, A.39
Hayward, I.40
Radinsky, R.41
Boone, T.42
Kendall, R.43
more..
-
24
-
-
78149239651
-
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
-
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4706-4713
-
-
Peeters, M.1
Price, T.J.2
Cervantes, A.3
Sobrero, A.F.4
Ducreux, M.5
Hotko, Y.6
Andre, T.7
Chan, E.8
Lordick, F.9
Punt, C.J.10
Strickland, A.H.11
Wilson, G.12
Ciuleanu, T.E.13
Roman, L.14
Van Cutsem, E.15
Tzekova, V.16
Collins, S.17
Oliner, K.S.18
Rong, A.19
Gansert, J.20
more..
-
25
-
-
84870659220
-
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double-blind, placebo-controlled, phase 2 study
-
Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B (2012) AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 118(24): 6152-6161.
-
(2012)
Cancer
, vol.118
, Issue.24
, pp. 6152-6161
-
-
Rini, B.1
Szczylik, C.2
Tannir, N.M.3
Koralewski, P.4
Tomczak, P.5
Deptala, A.6
Dirix, L.Y.7
Fishman, M.8
Ramlau, R.9
Ravaud, A.10
Rogowski, W.11
Kracht, K.12
Sun, Y.N.13
Bass, M.B.14
Puhlmann, M.15
Escudier, B.16
-
26
-
-
4143101374
-
Relevance of different UGT1A1 polymorphisms in irinotecaninduced toxicity: A molecular and clinical study of 75 patients
-
Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E (2004) Relevance of different UGT1A1 polymorphisms in irinotecaninduced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10: 5151-5159.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5151-5159
-
-
Rouits, E.1
Boisdron-Celle, M.2
Dumont, A.3
Guerin, O.4
Morel, A.5
Gamelin, E.6
-
27
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
-
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Diaz-Rubio, E.3
Scheithauer, W.4
Figer, A.5
Wong, R.6
Koski, S.7
Lichinitser, M.8
Yang, T.S.9
Rivera, F.10
Couture, F.11
Sirzen, F.12
Cassidy, J.13
-
28
-
-
33846392722
-
Soluble VCAM-1 and E-selectin in breast cancer: Relationship with staging and with the detection of circulating cancer cells
-
Silva HC, Garcao F, Coutinho EC, De Oliveira CF, Regateiro FJ (2006) Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells. Neoplasma 53: 538-543.
-
(2006)
Neoplasma
, vol.53
, pp. 538-543
-
-
Silva, H.C.1
Garcao, F.2
Coutinho, E.C.3
De Oliveira, C.F.4
Regateiro, F.J.5
-
29
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
30
-
-
1342290189
-
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
-
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237.
-
(2004)
J Clin Oncol
, vol.22
, pp. 229-237
-
-
Tournigand, C.1
Andre, T.2
Achille, E.3
Lledo, G.4
Flesh, M.5
Mery-Mignard, D.6
Quinaux, E.7
Couteau, C.8
Buyse, M.9
Ganem, G.10
Landi, B.11
Colin, P.12
Louvet, C.13
De Gramont, A.14
-
31
-
-
77954346705
-
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
-
Group EGW
-
Van Cutsem E, Nordlinger B, Cervantes A, Group EGW (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21(Suppl 5): v93-v97.
-
(2010)
Ann Oncol
, vol.21
, Issue.SUPPL. 5
-
-
Van Cutsem, E.1
Nordlinger, B.2
Cervantes, A.3
-
32
-
-
84875230621
-
Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase III trial (EFC10262-VELOUR)
-
Barcelona Spain (22-25 June 2011)
-
Van Cutsem E, Tabernero J, Lakomy R, Prausova J, Ruff P, Van Hazel G, Moiseyenko V, Ferry D, McKendrick J, Tellier A, Castan R, Allegra C (2011) Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR). Presented at: 13th World Congress on Gastrointestinal Cancer Barcelona, Spain (22-25 June 2011).
-
(2011)
13th World Congress on Gastrointestinal Cancer
-
-
Van Cutsem, E.1
Tabernero, J.2
Lakomy, R.3
Prausova, J.4
Ruff, P.5
Van Hazel, G.6
Moiseyenko, V.7
Ferry, D.8
McKendrick, J.9
Tellier, A.10
Castan, R.11
Allegra, C.12
-
33
-
-
1942453306
-
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
-
van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40: 939-950.
-
(2004)
Eur J Cancer
, vol.40
, pp. 939-950
-
-
Van Kuilenburg, A.B.1
-
34
-
-
0031750177
-
Serum concentrations of soluble adhesion molecules in patients with colorectal cancer
-
Velikova G, Banks RE, Gearing A, Hemingway I, Forbes MA, Preston SR, Hall NR, Jones M, Wyatt J, Miller K, Ward U, Al-Maskatti J, Singh SM, Finan PJ, Ambrose NS, Primrose JN, Selby PJ (1998) Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer 77: 1857-1863.
-
(1998)
Br J Cancer
, vol.77
, pp. 1857-1863
-
-
Velikova, G.1
Banks, R.E.2
Gearing, A.3
Hemingway, I.4
Forbes, M.A.5
Preston, S.R.6
Hall, N.R.7
Jones, M.8
Wyatt, J.9
Miller, K.10
Ward, U.11
Al-Maskatti, J.12
Singh, S.M.13
Finan, P.J.14
Ambrose, N.S.15
Primrose, J.N.16
Selby, P.J.17
-
35
-
-
78650924656
-
Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer
-
Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ (2011) Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 104: 51-59.
-
(2011)
Br J Cancer
, vol.104
, pp. 51-59
-
-
Volkova, E.1
Willis, J.A.2
Wells, J.E.3
Robinson, B.A.4
Dachs, G.U.5
Currie, M.J.6
-
36
-
-
17644379417
-
Placenta growth factor expression is correlated with survival of patients with colorectal cancer
-
Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu JJ, Wu CH, Su YN, Hsieh FJ, Wong JM (2005) Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 54: 666-672.
-
(2005)
Gut
, vol.54
, pp. 666-672
-
-
Wei, S.C.1
Tsao, P.N.2
Yu, S.C.3
Shun, C.T.4
Tsai-Wu, J.J.5
Wu, C.H.6
Su, Y.N.7
Hsieh, F.J.8
Wong, J.M.9
-
37
-
-
67649921334
-
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study
-
Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27: 3020-3026.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3020-3026
-
-
Willett, C.G.1
Duda, D.G.2
Di Tomaso, E.3
Boucher, Y.4
Ancukiewicz, M.5
Sahani, D.V.6
Lahdenranta, J.7
Chung, D.C.8
Fischman, A.J.9
Lauwers, G.Y.10
Shellito, P.11
Czito, B.G.12
Wong, T.Z.13
Paulson, E.14
Poleski, M.15
Vujaskovic, Z.16
Bentley, R.17
Chen, H.X.18
Clark, J.W.19
Jain, R.K.20
more..
-
38
-
-
0037114332
-
Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers
-
Yamashita K, Mikami Y, Ikeda M, Yamamura M, Kubozoe T, Urakami A, Yoshida K, Kimoto M, Tsunoda T (2002) Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers. Cancer Lett 188: 231-236.
-
(2002)
Cancer Lett
, vol.188
, pp. 231-236
-
-
Yamashita, K.1
Mikami, Y.2
Ikeda, M.3
Yamamura, M.4
Kubozoe, T.5
Urakami, A.6
Yoshida, K.7
Kimoto, M.8
Tsunoda, T.9
|